Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Atopic Dermatitis-Pipeline Review, H1 2015

Atopic Dermatitis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Atopic Dermatitis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Atopic Dermatitis-Pipeline Review, H1 2015', provides an overview of the Atopic Dermatitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Atopic Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atopic Dermatitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Atopic Dermatitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Atopic Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Atopic Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

Atopic Dermatitis Overview 12

Therapeutics Development 13

Pipeline Products for Atopic Dermatitis-Overview 13

Pipeline Products for Atopic Dermatitis-Comparative Analysis 14

Atopic Dermatitis-Therapeutics under Development by Companies 15

Atopic Dermatitis-Therapeutics under Investigation by Universities/Institutes 22

Atopic Dermatitis-Pipeline Products Glance 23

Late Stage Products 23

Clinical Stage Products 24

Early Stage Products 25

Unknown Stage Products 26

Atopic Dermatitis-Products under Development by Companies 27

Atopic Dermatitis-Products under Investigation by Universities/Institutes 34

Atopic Dermatitis-Companies Involved in Therapeutics Development 35

AlbireoPharma 35

Almirall, S.A. 36

Amorepacific Corporation 37

Anacor Pharmaceuticals, Inc. 38

AnaMar AB 39

AnaptysBio, Inc. 40

AnGes MG, Inc. 41

Aquinox Pharmaceuticals Inc. 42

arGEN-X BV 43

Blueberry Therapeutics Ltd 44

Brickell Biotech, Inc. 45

Bristol-Myers Squibb Company 46

Celgene Corporation 47

ChemoCentryx, Inc. 48

ChironWells GmbH 49

Chugai Pharmaceutical Co., Ltd. 50

Circassia Pharmaceuticals Plc 51

Creabilis SA 52

Dermira Inc. 53

Eisai Co., Ltd. 54

F. Hoffmann-La Roche Ltd. 55

FAES Farma SA 56

Foamix Pharmaceuticals Ltd. 57

Fountain Biopharma Inc. 58

Grupo Ferrer Internacional, S.A. 59

Han Wha Pharma Co., Ltd. 60

HanAll Biopharma Co., Ltd. 61

Herantis Pharma plc. 62

IMMD Inc. 63

Inflamalps SA 64

Japan Tobacco Inc. 65

Johnson & Johnson 66

Kyowa Hakko Kirin Co., Ltd. 67

LegoChem Biosciences, Inc 68

LEO Pharma A/S 69

Madam Therapeutics B.V. 70

MedImmune, LLC 71

Mitsubishi Tanabe Pharma Corporation 72

Nabriva Therapeutics AG 73

NeoPharm Co., Ltd. 74

Novan, Inc. 75

Novartis AG 76

Nuvo Research Inc. 77

Otsuka Holdings Co., Ltd. 78

Oxagen Limited 79

Pergamum AB 80

Pfizer Inc. 81

Pharis Biotec GmbH 82

Pharmedartis GmbH 83

Promius Pharma, LLC 84

Provectus Biopharmaceuticals, Inc. 85

R-Tech Ueno, Ltd. 86

Regeneron Pharmaceuticals, Inc. 87

Spherium Biomed S.L. 88

sterna biologicals Gmbh & Co KG 89

Sun Pharma Advanced Research Company Ltd. 90

SWITCH Biotech LLC 91

Takeda Pharmaceutical Company Limited 92

Thesan Pharmaceuticals, Inc. 93

Valeant Pharmaceuticals International, Inc. 94

Vicore Pharma AB 95

Vitae Pharmaceuticals, Inc. 96

VivaCell Biotechnology Espana S.L. 97

Welichem Biotech Inc. 98

Xencor, Inc. 99

Yungjin Pharm Ind. Co., Ltd. 100

Ziarco Pharma Ltd 101

Atopic Dermatitis-Therapeutics Assessment 102

Assessment by Monotherapy Products 102

Assessment by Combination Products 103

Assessment by Target 104

Assessment by Mechanism of Action 107

Assessment by Route of Administration 110

Assessment by Molecule Type 112

Drug Profiles 114

(betamethasone dipropionate + bexarotene)-Drug Profile 114

A-3914-Drug Profile 115

A-5425-Drug Profile 116

AM-1030-Drug Profile 117

AN-2898-Drug Profile 118

AN-4161-Drug Profile 119

ANB-020-Drug Profile 120

apremilast-Drug Profile 121

Aptamers to Inhibit Galectin-3 for Atopic Dermatitis-Drug Profile 124

AQX-1125-Drug Profile 125

ARGX-112-Drug Profile 127

ARN-077-Drug Profile 128

BB-2702-Drug Profile 129

BBI-2111-Drug Profile 130

BBI-5000-Drug Profile 131

BC-7013-Drug Profile 132

Biologic for Atopic Dermatitis and Eczema-Drug Profile 133

BMS-981164-Drug Profile 134

BPR-277-Drug Profile 135

C-21-Drug Profile 136

CBP-174-Drug Profile 138

CBP-201-Drug Profile 139

CCX-6239-Drug Profile 140

CDE-001-Drug Profile 141

CIR-001-Drug Profile 142

Cis-Urocanic Acid-Drug Profile 143

CNTO-7160-Drug Profile 146

cobamamide-Drug Profile 147

crisaborole-Drug Profile 148

CT-1x1-Drug Profile 150

CT-1x2-Drug Profile 151

CT-1x3-Drug Profile 152

CT-327-Drug Profile 153

DFD-06-Drug Profile 155

DPK-060-Drug Profile 156

DRM-02-Drug Profile 157

Drug for Atopic Dermatitis-Drug Profile 158

Drugs for Dermatitis-Drug Profile 159

Drugs to Antagonize TNFR-1 for Atopic Dermatitis-Drug Profile 160

dupilumab-Drug Profile 161

E-6005-Drug Profile 164

FB-825-Drug Profile 165

fevipiprant-Drug Profile 166

FIB-116-Drug Profile 168

Furestem-AD-Drug Profile 169

HS-378-Drug Profile 170

IMD-0354-Drug Profile 171

JTE-052-Drug Profile 172

KHK-4577-Drug Profile 173

KTG-001-Drug Profile 174

LCB-030110-Drug Profile 175

lebrikizumab-Drug Profile 176

LEKTI-6-Drug Profile 178

LEO-39652-Drug Profile 179

ligelizumab-Drug Profile 180

MC-207-Drug Profile 182

MLR-1130-Drug Profile 183

mometasone furoate-Drug Profile 184

N-oleoylethanolamine-Drug Profile 185

nemolizumab-Drug Profile 186

NPB-3-Drug Profile 187

NPH-12-Drug Profile 188

NVN-4428-Drug Profile 189

OC-2417-Drug Profile 190

OC-459-Drug Profile 191

OLX-103-Drug Profile 193

omiganan pentahydrochloride-Drug Profile 194

OPA-15406-Drug Profile 196

P-10-Drug Profile 197

PAC-14028-Drug Profile 198

PDI-192-Drug Profile 200

Peptide to Antagonize CX3CR1 for Atopic Dermatitis-Drug Profile 201

Peptides to Antagonize TNFR-1 for Atopic Dermatitis-Drug Profile 202

PH-10-Drug Profile 203

PL-601-Drug Profile 205

PMA-101R-Drug Profile 206

PMA-201-Drug Profile 207

PMA-411R-Drug Profile 208

Q-301-Drug Profile 209

roflumilast-Drug Profile 210

RTU-1096-Drug Profile 213

S-414114-Drug Profile 214

SB-011-Drug Profile 216

SIG-1311-Drug Profile 217

SIG-1322-Drug Profile 218

Small Molecule to Modulate SIPR for Atopic Dermatitis-Drug Profile 219

Small Molecules for Atopic Dermatitis-Drug Profile 220

Small Molecules to Inhibit Kinase for Inflammatory Diseases-Drug Profile 221

SP-14019-Drug Profile 222

SUN-0597-Drug Profile 223

SWT-01113-Drug Profile 225

SWT-05141-Drug Profile 226

Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders-Drug Profile 227

TA-7906-Drug Profile 228

tofacitinib-Drug Profile 229

tralokinumab-Drug Profile 233

ustekinumab-Drug Profile 235

VTP-38543-Drug Profile 238

WBI-1001-Drug Profile 239

WF-10 liposomal-Drug Profile 240

XmAb-7195-Drug Profile 241

YJC-10592-Drug Profile 242

ZPL-3893787-Drug Profile 243

ZPL-5212372-Drug Profile 244

Atopic Dermatitis-Recent Pipeline Updates 245

Atopic Dermatitis-Dormant Projects 286

Atopic Dermatitis-Discontinued Products 294

Atopic Dermatitis-Product Development Milestones 296

Featured News & Press Releases 296

Appendix 304

Methodology 304

Coverage 304

Secondary Research 304

Primary Research 304

Expert Panel Validation 304

Contact Us 304

Disclaimer 305

List of Tables

Number of Products under Development for Atopic Dermatitis, H1 2015 20

Number of Products under Development for Atopic Dermatitis-Comparative Analysis, H1 2015 21

Number of Products under Development by Companies, H1 2015 23

Number of Products under Development by Companies, H1 2015 (Contd..1) 24

Number of Products under Development by Companies, H1 2015 (Contd..2) 25

Number of Products under Development by Companies, H1 2015 (Contd..3) 26

Number of Products under Development by Companies, H1 2015 (Contd..4) 27

Number of Products under Development by Companies, H1 2015 (Contd..5) 28

Number of Products under Investigation by Universities/Institutes, H1 2015 29

Comparative Analysis by Late Stage Development, H1 2015 30

Comparative Analysis by Clinical Stage Development, H1 2015 31

Comparative Analysis by Early Stage Development, H1 2015 32

Comparative Analysis by Unknown Stage Development, H1 2015 33

Products under Development by Companies, H1 2015 34

Products under Development by Companies, H1 2015 (Contd..1) 35

Products under Development by Companies, H1 2015 (Contd..2) 36

Products under Development by Companies, H1 2015 (Contd..3) 37

Products under Development by Companies, H1 2015 (Contd..4) 38

Products under Development by Companies, H1 2015 (Contd..5) 39

Products under Development by Companies, H1 2015 (Contd..6) 40

Products under Investigation by Universities/Institutes, H1 2015 41

Atopic Dermatitis-Pipeline by AlbireoPharma, H1 2015 42

Atopic Dermatitis-Pipeline by Almirall, S.A., H1 2015 43

Atopic Dermatitis-Pipeline by Amorepacific Corporation, H1 2015 44

Atopic Dermatitis-Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 45

Atopic Dermatitis-Pipeline by AnaMar AB, H1 2015 46

Atopic Dermatitis-Pipeline by AnaptysBio, Inc., H1 2015 47

Atopic Dermatitis-Pipeline by AnGes MG, Inc., H1 2015 48

Atopic Dermatitis-Pipeline by Aquinox Pharmaceuticals Inc., H1 2015 49

Atopic Dermatitis-Pipeline by arGEN-X BV, H1 2015 50

Atopic Dermatitis-Pipeline by Blueberry Therapeutics Ltd, H1 2015 51

Atopic Dermatitis-Pipeline by Brickell Biotech, Inc., H1 2015 52

Atopic Dermatitis-Pipeline by Bristol-Myers Squibb Company, H1 2015 53

Atopic Dermatitis-Pipeline by Celgene Corporation, H1 2015 54

Atopic Dermatitis-Pipeline by ChemoCentryx, Inc., H1 2015 55

Atopic Dermatitis-Pipeline by ChironWells GmbH, H1 2015 56

Atopic Dermatitis-Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 57

Atopic Dermatitis-Pipeline by Circassia Pharmaceuticals Plc, H1 2015 58

Atopic Dermatitis-Pipeline by Creabilis SA, H1 2015 59

Atopic Dermatitis-Pipeline by Dermira Inc., H1 2015 60

Atopic Dermatitis-Pipeline by Eisai Co., Ltd., H1 2015 61

Atopic Dermatitis-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 62

Atopic Dermatitis-Pipeline by FAES Farma SA, H1 2015 63

Atopic Dermatitis-Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 64

Atopic Dermatitis-Pipeline by Fountain Biopharma Inc., H1 2015 65

Atopic Dermatitis-Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 66

Atopic Dermatitis-Pipeline by Han Wha Pharma Co., Ltd., H1 2015 67

Atopic Dermatitis-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 68

Atopic Dermatitis-Pipeline by Herantis Pharma plc., H1 2015 69

Atopic Dermatitis-Pipeline by IMMD Inc., H1 2015 70

Atopic Dermatitis-Pipeline by Inflamalps SA, H1 2015 71

Atopic Dermatitis-Pipeline by Japan Tobacco Inc., H1 2015 72

Atopic Dermatitis-Pipeline by Johnson & Johnson, H1 2015 73

Atopic Dermatitis-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 74

Atopic Dermatitis-Pipeline by LegoChem Biosciences, Inc, H1 2015 75

Atopic Dermatitis-Pipeline by LEO Pharma A/S, H1 2015 76

Atopic Dermatitis-Pipeline by Madam Therapeutics B.V., H1 2015 77

Atopic Dermatitis-Pipeline by MedImmune, LLC, H1 2015 78

Atopic Dermatitis-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 79

Atopic Dermatitis-Pipeline by Nabriva Therapeutics AG, H1 2015 80

Atopic Dermatitis-Pipeline by NeoPharm Co., Ltd., H1 2015 81

Atopic Dermatitis-Pipeline by Novan, Inc., H1 2015 82

Atopic Dermatitis-Pipeline by Novartis AG, H1 2015 83

Atopic Dermatitis-Pipeline by Nuvo Research Inc., H1 2015 84

Atopic Dermatitis-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 85

Atopic Dermatitis-Pipeline by Oxagen Limited, H1 2015 86

Atopic Dermatitis-Pipeline by Pergamum AB, H1 2015 87

Atopic Dermatitis-Pipeline by Pfizer Inc., H1 2015 88

Atopic Dermatitis-Pipeline by Pharis Biotec GmbH, H1 2015 89

Atopic Dermatitis-Pipeline by Pharmedartis GmbH, H1 2015 90

Atopic Dermatitis-Pipeline by Promius Pharma, LLC, H1 2015 91

Atopic Dermatitis-Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 92

Atopic Dermatitis-Pipeline by R-Tech Ueno, Ltd., H1 2015 93

Atopic Dermatitis-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 94

Atopic Dermatitis-Pipeline by Spherium Biomed S.L., H1 2015 95

Atopic Dermatitis-Pipeline by sterna biologicals Gmbh & Co KG, H1 2015 96

Atopic Dermatitis-Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 97

Atopic Dermatitis-Pipeline by SWITCH Biotech LLC, H1 2015 98

Atopic Dermatitis-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 99

Atopic Dermatitis-Pipeline by Thesan Pharmaceuticals, Inc., H1 2015 100

Atopic Dermatitis-Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 101

Atopic Dermatitis-Pipeline by Vicore Pharma AB, H1 2015 102

Atopic Dermatitis-Pipeline by Vitae Pharmaceuticals, Inc., H1 2015 103

Atopic Dermatitis-Pipeline by VivaCell Biotechnology Espana S.L., H1 2015 104

Atopic Dermatitis-Pipeline by Welichem Biotech Inc., H1 2015 105

Atopic Dermatitis-Pipeline by Xencor, Inc., H1 2015 106

Atopic Dermatitis-Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 107

Atopic Dermatitis-Pipeline by Ziarco Pharma Ltd, H1 2015 108

Assessment by Monotherapy Products, H1 2015 109

Assessment by Combination Products, H1 2015 110

Number of Products by Stage and Target, H1 2015 112

Number of Products by Stage and Mechanism of Action, H1 2015 115

Number of Products by Stage and Route of Administration, H1 2015 118

Number of Products by Stage and Molecule Type, H1 2015 120

Atopic Dermatitis Therapeutics-Recent Pipeline Updates, H1 2015 252

Atopic Dermatitis-Dormant Projects, H1 2015 293

Atopic Dermatitis-Dormant Projects (Contd..1), H1 2015 294

Atopic Dermatitis-Dormant Projects (Contd..2), H1 2015 295

Atopic Dermatitis-Dormant Projects (Contd..3), H1 2015 296

Atopic Dermatitis-Dormant Projects (Contd..4), H1 2015 297

Atopic Dermatitis-Dormant Projects (Contd..5), H1 2015 298

Atopic Dermatitis-Dormant Projects (Contd..6), H1 2015 299

Atopic Dermatitis-Dormant Projects (Contd..7), H1 2015 300

Atopic Dermatitis-Discontinued Products, H1 2015 301

Atopic Dermatitis-Discontinued Products (Contd..1), H1 2015 302

List of Figures

Number of Products under Development for Atopic Dermatitis, H1 2015 20

Number of Products under Development for Atopic Dermatitis-Comparative Analysis, H1 2015 21

Number of Products under Development by Companies, H1 2015 22

Number of Products under Investigation by Universities/Institutes, H1 2015 29

Comparative Analysis by Late Stage Development, H1 2015 30

Comparative Analysis by Clinical Stage Development, H1 2015 31

Comparative Analysis by Early Stage Products, H1 2015 32

Assessment by Monotherapy Products, H1 2015 109

Number of Products by Top 10 Targets, H1 2015 111

Number of Products by Stage and Top 10 Targets, H1 2015 111

Number of Products by Top 10 Mechanism of Actions, H1 2015 114

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 114

Number of Products by Top 10 Routes of Administration, H1 2015 117

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 117

Number of Products by Top 10 Molecule Types, H1 2015 119

Number of Products by Stage and Top 10 Molecule Types, H1 2015 119

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AlbireoPharma

Almirall, S.A.

Amorepacific Corporation

Anacor Pharmaceuticals, Inc.

AnaMar AB

AnaptysBio, Inc.

AnGes MG, Inc.

Aquinox Pharmaceuticals Inc.

arGEN-X BV

Blueberry Therapeutics Ltd

Brickell Biotech, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

ChemoCentryx, Inc.

ChironWells GmbH

Chugai Pharmaceutical Co., Ltd.

Circassia Pharmaceuticals Plc

Creabilis SA

Dermira Inc.

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd.

FAES Farma SA

Foamix Pharmaceuticals Ltd.

Fountain Biopharma Inc.

Grupo Ferrer Internacional, S.A.

Han Wha Pharma Co., Ltd.

HanAll Biopharma Co., Ltd.

Herantis Pharma plc.

IMMD Inc.

Inflamalps SA

Japan Tobacco Inc.

Johnson & Johnson

Kyowa Hakko Kirin Co., Ltd.

LegoChem Biosciences, Inc

LEO Pharma A/S

Madam Therapeutics B.V.

MedImmune, LLC

Mitsubishi Tanabe Pharma Corporation

Nabriva Therapeutics AG

NeoPharm Co., Ltd.

Novan, Inc.

Novartis AG

Nuvo Research Inc.

Otsuka Holdings Co., Ltd.

Oxagen Limited

Pergamum AB

Pfizer Inc.

Pharis Biotec GmbH

Pharmedartis GmbH

Promius Pharma, LLC

Provectus Biopharmaceuticals, Inc.

R-Tech Ueno, Ltd.

Regeneron Pharmaceuticals, Inc.

Spherium Biomed S.L.

sterna biologicals Gmbh & Co KG

Sun Pharma Advanced Research Company Ltd.

SWITCH Biotech LLC

Takeda Pharmaceutical Company Limited

Thesan Pharmaceuticals, Inc.

Valeant Pharmaceuticals International, Inc.

Vicore Pharma AB

Vitae Pharmaceuticals, Inc.

VivaCell Biotechnology Espana S.L.

Welichem Biotech Inc.

Xencor, Inc.

Yungjin Pharm Ind. Co., Ltd.

Ziarco Pharma Ltd

pic Dermatitis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Atopic Dermatitis Therapeutic Products under Development, Key Players in Atopic Dermatitis Therapeutics, Atopic Dermatitis Pipeline Overview, Atopic Dermatitis Pipeline, Atopic Dermatitis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com